Detailed narrative
Ebstracell Regulatory and Manufacturing Progress
INmune Bio secured formal MHRA alignment for Ebstracell, covering CMC, non-clinical, and clinical evidence, providing a defined path for conditional marketing authorization in R-DEB. The MHRA also approved the pediatric investigation plan and recognized Mission EB data for clinically meaningful symptomatic benefits, particularly in pain and pruritus. Manufacturing readiness advanced with successful processing of commercial-ready umbilical cord tissue and transfer of MSC isolation to the commercial facility, supported by an expanded Anthony Nolan Agreement for scalable supply.
EXPRO Clinical Development and Strategic Focus
EXPRO received FDA Fast-Track designation for early Alzheimer's disease. The Phase 2 MINDFUL study demonstrated a statistically significant treatment effect (p=0.0028) on white matter myelin MRI biomarkers, with a Cohen's effect size of 0.46 (0.59 in the biomarker-enriched population). These data, along with successful end-of-Phase II alignment with the FDA and publication in NPJ Dementia, strengthen the clinical and regulatory foundation for a Phase 2b3 program. While Alzheimer's remains the clinical priority, the company evaluates strategic partnership opportunities for EXPRO.
Cordstrom Platform Expansion
The Cordstrom platform patent application entered the US national phase, potentially providing broad protection into at least 2045. A newly formed scientific advisory board (SAB) will strengthen Ebstracell's late-stage development and prioritize additional disease-specific applications of the platform, focusing on phase three design, translational biomarker identification, potency assays, and indication selection.
Financial Overview and Capital Strategy
The company reported a net loss of $1.3 million for Q2 FY26, significantly lower than the prior year due to an R&D benefit. Cash and cash equivalents stood at $18.4 million as of June 30, 2026, supplemented by a $4.2 million Australian R&D tax rebate. Existing cash resources are believed to fund operations into Q2 2027. Management emphasized a cautious approach to capital, aiming to fund operations through small, judicious raises, leveraging an ATM, and being sensitive to dilution given their significant founder ownership.
R-DEB Market Opportunity and Pricing
The R-DEB patient population is estimated at 2,000-3,000 in the US, similar in Europe, and around 800 in the UK, with approximately 60% being children. The company expects Ebstracell pricing in the UK to be around £400,000-£500,000 per year per child, with pricing negotiations beginning after MAA filing. Hospitals in the UK have mechanisms to fund medication before final reimbursement negotiations.